argenx SE (ARGX)Healthcare | Biotechnology | Amsterdam, Netherlands | NasdaqGS
876.25 USD
-1.37
(-0.156%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 876.25 |
Hot Take ↕ | July 11, 2026, 2:50 a.m. EDT
Argenx stands out as a high-growth biotechnology leader with a fortress balance sheet and accelerating earnings. The company has delivered eight consecutive years of positive annual returns, validating its business model over the long cycle. While the valuation multiples are elevated, reflecting high expectations for future milestones, the underlying fundamentals—specifically the 62 percent revenue expansion and net cash position—support a premium price. Short-term technicals remain constructive with the stock trading above its 50-day average, though recent volatility suggests some profit-taking near the yearly high. Options activity indicates speculative interest is skewed toward upside targets well above the current price. For investors willing to tolerate valuation risk in exchange for growth potential, the risk-reward profile appears favorable, but the absence of dividend income means all returns rely on capital appreciation. |
| Model | MAE |
|---|---|
| MSTL_70 ✓ | 0.043853 |
| AutoTheta | 0.044243 |
| MSTL | 0.049283 |
| AutoARIMA | 0.049487 |
| AutoETS | 0.049487 |
| MSTL_70_84 | 0.056638 |
| MSTL_84 | 0.060434 |
Forecast horizon: 60 days | Selected: MSTL_70
| Forecast Reliability | |
|---|---|
| Score | 42% |
| H-stat | 5.64 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.118 |
| Excess Kurtosis | -0.81 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.644 |
| Revenue per Share | 3.08136 |
| Market Cap | 54,761,213,952 |
| Trailing P/E | 38.89 |
| Forward P/E | 23.82 |
| Beta | -0.02 |
| Profit Margins | 31.40% |
| Website | https://argenx.com |
As of July 11, 2026, 2:50 a.m. EDT: Speculators are positioning for continued upside with call open interest significantly outweighing put open interest at strikes above the current price, particularly in the 1000 to 1300 range. Implied volatility sits in the 40-50 percent range, indicating heightened uncertainty or anticipation of catalysts. While there is defensive put buying near the 750 to 900 level, the aggregate positioning leans bullish, suggesting traders expect the stock to maintain its upward trajectory despite recent intraday volatility.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.5636046 |
| Address1 | Laarderhoogtweg 25 |
| All Time High | 953.58 |
| All Time Low | 17.33 |
| Ask | 910.95 |
| Ask Size | 2 |
| Average Analyst Rating | 1.5 - Buy |
| Average Daily Volume10 Day | 329,320 |
| Average Daily Volume3 Month | 340,508 |
| Average Volume | 340,508 |
| Average Volume10Days | 329,320 |
| Beta | -0.022 |
| Bid | 875.06 |
| Bid Size | 1 |
| Book Value | 4.73348 |
| City | Amsterdam |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Netherlands |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 876.25 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 878.16 |
| Day Low | 855.97 |
| Debt To Equity | 0.644 |
| Earnings Call Timestamp End | 1,778,157,000 |
| Earnings Call Timestamp Start | 1,778,157,000 |
| Earnings Growth | 1.14 |
| Earnings Quarterly Growth | 1.16 |
| Earnings Timestamp | 1,784,809,800 |
| Earnings Timestamp End | 1,784,809,800 |
| Earnings Timestamp Start | 1,784,809,800 |
| Ebitda | 1,318,290,304 |
| Ebitda Margins | 0.27798 |
| Enterprise To Ebitda | 1,027.977 |
| Enterprise To Revenue | 285.752 |
| Enterprise Value | 1,355,172,282,368 |
| Eps Current Year | 22.57867 |
| Eps Forward | 36.7829 |
| Eps Trailing Twelve Months | 22.53 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 848.631 |
| Fifty Day Average Change | 27.619019 |
| Fifty Day Average Change Percent | 0.03254538 |
| Fifty Two Week Change Percent | 56.36046 |
| Fifty Two Week High | 953.58 |
| Fifty Two Week High Change | -77.33002 |
| Fifty Two Week High Change Percent | -0.08109442 |
| Fifty Two Week Low | 554.59 |
| Fifty Two Week Low Change | 321.65997 |
| Fifty Two Week Low Change Percent | 0.57999593 |
| Fifty Two Week Range | 554.59 - 953.58 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,495,114,200,000 |
| Float Shares | 1,548,794,886 |
| Forward Eps | 36.7829 |
| Forward P E | 23.82221 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 1,863 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.58106 |
| Gross Profits | 2,755,672,064 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.000030000001 |
| Held Percent Institutions | 0.47636002 |
| Implied Shares Outstanding | 62,494,970 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands. |
| Long Name | argenx SE |
| Market | us_market |
| Market Cap | 54,761,213,952 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_62120637 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | 1,489,035,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 54,091,902,888 |
| Number Of Analyst Opinions | 23 |
| Open | 870.6 |
| Operating Margins | 0.30008 |
| Payout Ratio | 0.0 |
| Peg Ratio | 1.49 |
| Phone | 31 10 703 8441 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 876.25 |
| Post Market Time | 1,783,976,688 |
| Previous Close | 877.62 |
| Price Eps Current Year | 38.80875 |
| Price Hint | 2 |
| Price To Book | 185.11751 |
| Price To Sales Trailing12 Months | 11.546984 |
| Profit Margins | 0.31398 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.52 |
| Region | US |
| Regular Market Change | -1.37 |
| Regular Market Change Percent | -0.156103 |
| Regular Market Day High | 878.16 |
| Regular Market Day Low | 855.97 |
| Regular Market Day Range | 855.97 - 878.16 |
| Regular Market Open | 870.6 |
| Regular Market Previous Close | 877.62 |
| Regular Market Price | 876.25 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 373,925 |
| Revenue Growth | 0.626 |
| Revenue Per Share | 3.08136 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 62,187,771 |
| Shares Percent Shares Out | 0.0233 |
| Shares Short | 1,450,472 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 1,807,173 |
| Short Name | argenx SE |
| Short Percent Of Float | 0.0233 |
| Short Ratio | 3.58 |
| Source Interval | 15 |
| Symbol | ARGX |
| Target High Price | 1,287.3228 |
| Target Low Price | 677.5119 |
| Target Mean Price | 1,049.1538 |
| Target Median Price | 1,039.2401 |
| Total Cash | 4,440,038,912 |
| Total Cash Per Share | 2.862 |
| Total Debt | 47,160,000 |
| Total Revenue | 4,742,469,120 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 22.53 |
| Trailing P E | 38.892586 |
| Trailing Peg Ratio | 1.4912 |
| Triggerable | 1 |
| Two Hundred Day Average | 821.97186 |
| Two Hundred Day Average Change | 54.278137 |
| Two Hundred Day Average Change Percent | 0.066034056 |
| Type Disp | Equity |
| Volume | 373,925 |
| Website | https://argenx.com |
| Zip | 1,101 EB |